- Home
- CSBR
as of 03-09-2026 3:22pm EST
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
| Founded: | 1985 | Country: | United States |
| Employees: | N/A | City: | BALTIMORE |
| Market Cap: | 82.7M | IPO Year: | 2015 |
| Target Price: | $12.00 | AVG Volume (30 days): | 5.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | 161.11 |
| 52 Week Low/High: | $5.59 - $10.25 | Next Earning Date: | 03-30-2026 |
| Revenue: | $2,900,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4.84% | Revenue Growth (next year): | 11.51% |
| P/E Ratio: | -580.00 | Index: | N/A |
| Free Cash Flow: | 7.0M | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Dec 15, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLDec 15, 2025 · 100% conf.
1D
-7.02%
$7.39
5D
-13.91%
$6.84
20D
-10.08%
$7.15
csbr-202512150000771856false00007718562025-12-152025-12-15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 15, 2025
CHAMPIONS ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
Item 2.02.Results of Operations and Financial Condition.
On December 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated December 15, 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CHAMPIONS ONCOLOGY, INC.
(Registrant)
Date: December 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Sep 15, 2025
Q2 2025 Earnings
8-KSep 15, 2025
csbr-202509150000771856false00007718562025-09-152025-09-15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 15, 2025
CHAMPIONS ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
Item 2.02.Results of Operations and Financial Condition.
On September 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated September 15, 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CHAMPIONS ONCOLOGY, INC.
(Registrant)
Date: September 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 23, 2025
Q2 2025 Earnings
8-KJul 23, 2025
csbr-202507230000771856false00007718562025-07-232025-07-23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 23, 2025
CHAMPIONS ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
Item 2.02.Results of Operations and Financial Condition.
On July 23, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 23, 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CHAMPIONS ONCOLOGY, INC.
(Registrant)
Date: July 23, 2025By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Compare CSBR vs Leading Stocks
See how CSBR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CSBR Champions Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.